| Dr Veronika Stock, MD | |
|
747 Main Street, Concord, MA 01742 | |
| (617) 356-7879 | |
| Not Available |
| Full Name | Dr Veronika Stock |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 21 Years |
| Location | 747 Main Street, Concord, Massachusetts |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487970059 | NPI | - | NPPES |
| 258048 | Other | MA | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 258048 (Massachusetts) | Primary |
| Entity Name | The Mclean Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114979580 PECOS PAC ID: 9436040961 Enrollment ID: O20040323001228 |
News Archive
Hypertrophic cardiomyopathy (HCM), an abnormal thickening of the heart, affects more than 500,000 Americans, making it more common than better-known conditions such as Crohn's disease, Multiple Sclerosis and Anorexia Nervosa.
In living organisms, free metal ions are stored and transported through proteins assembled into highly ordered structures such as protein cages via a reaction called biomineralization.
As emergent pathogens like coronavirus and climate-related health challenges like wildfire smoke plague human populations, the University of Montana has received funding for a center dedicated to understanding and addressing public health challenges to Montana and the region.
Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.
Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Veronika Stock, MD 60 Thoreau St # 130, Concord, MA 01742-2456 Ph: (617) 356-7879 | Dr Veronika Stock, MD 747 Main Street, Concord, MA 01742 Ph: (617) 356-7879 |
News Archive
Hypertrophic cardiomyopathy (HCM), an abnormal thickening of the heart, affects more than 500,000 Americans, making it more common than better-known conditions such as Crohn's disease, Multiple Sclerosis and Anorexia Nervosa.
In living organisms, free metal ions are stored and transported through proteins assembled into highly ordered structures such as protein cages via a reaction called biomineralization.
As emergent pathogens like coronavirus and climate-related health challenges like wildfire smoke plague human populations, the University of Montana has received funding for a center dedicated to understanding and addressing public health challenges to Montana and the region.
Emergent BioSolutions Inc. today announced that it has been awarded five separate grants under the Qualifying Therapeutic Discovery Project (QTDP) Program to support continued development of its therapeutic programs in oncology and autoimmunity. The grants, with a total value of over $1.2 million, will fund Emergent's TRU-016 Small Modular ImmunoPharmaceutical (SMIP™), DRACO anti-CD3 SMIP, X1 TNF-based SCORPION™, X2 CTLA4-based SCORPION, and T-Scorps-based SCORPION therapeutic programs.
Sangamo BioSciences, Inc. announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
› Verified 1 days ago
Dr. Jeffrey Brian Hainsworth, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 131 Old Road To 9 Acre Cor Ste 430, Concord, MA 01742 Phone: 978-287-7481 Fax: 978-287-8983 | |
Aaron L. Frenz, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 330 Baker Ave, Concord, MA 01742 Phone: 978-287-9380 | |
Dr. Barbara P. Wissner, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 747 Main St, Suite 204, Concord, MA 01742 Phone: 978-371-2098 Fax: 978-371-2098 | |
Dr. Jennifer M Park, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 131 Old Road To 9 Acre Cor Ste 620, Concord, MA 01742 Phone: 703-403-4204 Fax: 571-446-4015 | |
Robert Parker Hopkins, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1266 Main St, Concord, MA 01742 Phone: 978-369-5454 Fax: 978-369-5454 | |
Dr. Stuart Wachter, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: John Cuming Bldg, 131 Ornac, Suite 580, Concord, MA 01742 Phone: 978-371-9690 Fax: 978-371-9691 | |
Lloyd Franklin Price, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 152 Holdenwood Rd, Concord, MA 01742 Phone: 978-369-1869 Fax: 978-371-2593 |